Company: LRHC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032211
Chunk: 3041

Company: La Rosa Holdings Corp.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 9C
Chunk 3041
---
 She has been with BioCorRx since
October 2012. Ms. Felix is one of the founders and President of BioCorRx Pharmaceuticals Inc., a majority owned subsidiary of
BioCorRx Inc. Prior to joining BioCorRx, her experience was in the private sector and public accounting. Since October 2021, Ms.
Felix has been serving as a member of the Board of Directors of Siyata Mobile, Inc. (Nasdaq: SYTA), as an independent director, a
chairperson of the Audit Committee, and a member of Compensation Committee and Nominating and Corporate Governance Committee. Since
January 9, 2023, Ms. Felix has also been serving as a member of the Board of Directors of Avalon GloboCare Corp. (Nasdaq: ALBT), as
an independent director and the Chair of the Compensation Committee. Ms. Felix has expertise in finance, accounting, company-wide
operations, budgeting, and internal control principles including GAAP, SEC, and Sarbanes-Oxley Act compliance. She has a thorough
knowledge of federal and state regulations and has successfully managed and produced SEC regulatory filings. She also has extensive
experience in developing and managing financial operations. Ms. Felix holds a Bachelor of Science in Accounting from the University
of Phoenix. She is also an MBA candidate at D’Amore-McKim School of Business, Northeastern University. The Board believes that
Ms. Felix is qualified to serve as a director of the Board of the Company because of her extensive investment and executive-level
management experience, financial expertise, and extensive experience serving as a board member of public companies.

56

Corporate Governance

The business and affairs of
our Company are managed under the direction of the Board. 

Term of Office

Directors serve until the
next annual meeting of stockholders and their respective successors are elected and qualified, subject to the earlier of their death,
resignation or removal. Our executive officers are elected by, and serve at the discretion of, our Board, subject to the terms of any
employment or other agreements. 

Our Controlled Company Status

Because, as of April 15, 2025,
Mr. La Rosa beneficially owns 8,984,650 shares of our Common Stock and 2,000 shares of our Series X Preferred Stock which has 10,000
votes per share when voting together with the Common Stock, which will represent in the aggregate 28,984,650 votes